Source comparison
Hexarelin Benefits: Research Comparison
Growth Hormone Secretion GHS-R1a receptor agonism in anterior pituitary 30-fold GH increase vs baseline (2 mcg/kg IV) GH-dependent Most potent synthetic GHRP; exceeds GHRP-6 by 40–50% without appetite stimulation Cardioprotection (Acute Ischemia) CD36 scavenge
This comparison does not assign a generated winner or score.
- Growth Hormone Secretion
- GHS-R1a receptor agonism in anterior pituitary
- 30-fold GH increase vs baseline (2 mcg/kg IV)
- GH-dependent
- Most potent synthetic GHRP; exceeds GHRP-6 by 40–50% without appetite stimulation
- Cardioprotection (Acute Ischemia)
- CD36 scavenger receptor activation in cardiomyocytes
- 36–42% reduction in infarct size (rat MI models)
- GH-independent (effect persists in GH-KO mice)
- Mechanistically distinct from GH pathway; rivals ischemic preconditioning protocols
- Cardioprotection (Chronic HF)
- CD36-mediated anti-inflammatory signaling, reduced fibrosis
- 28% improved cardiac output, 34% reduced LVEDP
- GH-independent
- Sustained benefit in heart failure models; targets maladaptive remodeling
- Neuroprotection (Ischemia)
- GHS-R1a in CNS + CD36 in microglia
- 52% reduction in neuronal apoptosis (cerebral ischemia models)
- Dual-pathway (both GH and CD36)
- Crosses blood-brain barrier; direct CNS receptor engagement confirmed
- Anti-Inflammatory (CNS)
- NLRP3 inflammasome suppression via CD36
- 70% reduction in IL-1β secretion (microglial cultures)
- Shifts microglia to M2 phenotype; relevant for neuroinflammatory and neurodegenerative research
- Cognitive Enhancement (Aging)
- GHS-R1a-mediated BDNF upregulation + reduced neuroinflammation
- 34% improved spatial memory, 52% increased hippocampal neurogenesis markers
- Dual-pathway
- Chronic treatment required; effect size comparable to other nootropic peptides